Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder (CKD-MBD) with Ravi Thadhani, M.D., M.P.H. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept in patients with end-stage renal disease with mineral and bone disorder.
Help employers find you! Check out all the jobs and post your resume.
